2025 Europe Acute Myeloid Leukemia Treatment Market Revenue Opportunities Report
Description
The 2025 Europe Acute Myeloid Leukemia Treatment Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Myeloid Leukemia Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Acute Myeloid Leukemia (AML) treatment market in Europe include Pfizer Inc., Bristol-Myers Squibb Company, Sanofi S.A., and Merck KGaA. Pfizer has a significant presence with MYLOTARG™, the first AML therapy approved in the EU that targets CD33-positive AML; it is used in combination chemotherapy for untreated patients, enhancing remission and relapse prevention. Bristol-Myers Squibb offers Onureg (oral azacitidine), improving overall and relapse-free survival, particularly for maintenance therapy post remission.
Sanofi plays a major role in leukemia therapeutics with its extensive R&D collaborations and strong global healthcare presence; it integrates innovative treatments through partnerships like with Regeneron Pharmaceuticals. Merck KGaA, a German leader with a long history, contributes with oncology treatments such as Erbitux and Bavencio and focuses on sustainable research and patient-centric leukemia therapies in Europe. Germany leads Europe’s AML market due to advanced healthcare infrastructure and oncology research, supporting these companies' growth and new product development.
These companies benefit from Europe’s favorable regulatory environment and investment in cancer research, with Germany and France being key markets due to advanced diagnostics and increasing patient populations. The European AML treatment market is projected to grow at a CAGR of approximately 10% through 2030, driven by ongoing clinical innovations and precision medicine approaches spearheaded by these pharmaceutical leaders.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Myeloid Leukemia Treatment Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Acute Myeloid Leukemia (AML) treatment market in Europe include Pfizer Inc., Bristol-Myers Squibb Company, Sanofi S.A., and Merck KGaA. Pfizer has a significant presence with MYLOTARG™, the first AML therapy approved in the EU that targets CD33-positive AML; it is used in combination chemotherapy for untreated patients, enhancing remission and relapse prevention. Bristol-Myers Squibb offers Onureg (oral azacitidine), improving overall and relapse-free survival, particularly for maintenance therapy post remission.
Sanofi plays a major role in leukemia therapeutics with its extensive R&D collaborations and strong global healthcare presence; it integrates innovative treatments through partnerships like with Regeneron Pharmaceuticals. Merck KGaA, a German leader with a long history, contributes with oncology treatments such as Erbitux and Bavencio and focuses on sustainable research and patient-centric leukemia therapies in Europe. Germany leads Europe’s AML market due to advanced healthcare infrastructure and oncology research, supporting these companies' growth and new product development.
These companies benefit from Europe’s favorable regulatory environment and investment in cancer research, with Germany and France being key markets due to advanced diagnostics and increasing patient populations. The European AML treatment market is projected to grow at a CAGR of approximately 10% through 2030, driven by ongoing clinical innovations and precision medicine approaches spearheaded by these pharmaceutical leaders.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
